NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02425891,A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130),https://clinicaltrials.gov/study/NCT02425891,,COMPLETED,"This multicenter, randomized, double-blind study evaluated the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents.",YES,Triple Negative Breast Cancer,"DRUG: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|DRUG: Nab-Paclitaxel|DRUG: Placebo","Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants, PFS was defined as the time from randomization to the occurrence of disease progression, as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause, whichever occurred first., Baseline up to approximately 34 months|PFS According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1), PFS was defined as the time from randomization to the occurrence of disease progression, as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause, whichever occurred first., Baseline up to approximately 34 months|Overall Survival (OS) in All Randomized Participants, OS was defined as the time from the date of randomization to the date of death from any cause., Baseline until death due to any cause (up to approximately 58 months)|OS in Participants With Detectable PD-L1, OS was defined as the time from the date of randomization to the date of death from any cause., Baseline until death due to any cause (up to approximately 58 months)","Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 in All Randomized Participants, An objective response was defined for participants with measurable disease at baseline as either a partial response (PR) or a complete response (CR) using RECIST v1.1., Baseline up to approximately 34 months|Percentage of Participants With an Objective Response of CR or PR According to RECIST v1.1 in Participants With Detectable PD-L1, An objective response was defined for participants with measurable disease at baseline as either a partial response (PR) or a complete response (CR) using RECIST v1.1., Baseline up to approximately 34 months|Duration of Response (DOR) According to RECIST v1.1 in All Randomized Participants, DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause, whichever occurred first., Baseline up to approximately 34 months|DOR Acccording to RECIST v1.1 in Participants With Detectable PD-L1, DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause, whichever occurred first., Baseline up to approximately 34 months|Time to Deterioration (TTD) in Global Health Status/Health Related Quality of Life According to European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) v3.0 in All Randomized Participants, Deterioration in GHS/HRQoL (Items 29, 30 of the EORTC QLQ C30) was defined by the following two criteria: 1. The time from randomization to the first time the participant's GHS/HRQoL scale score showed a \>=10-point decrease from the baseline scale score. A 10-point change was defined as the minimally important difference (MID). 2. The score decrease of \>= 10-points from baseline was held for at least two consecutive cycles, or an initial score decrease of \>= 10-points was followed by death or treatment discontinuation within 3 weeks from the last assessment., Baseline up to approximately 58 months|TTD in Global Health Status/Health Related Quality of Life According to EORTC QLQ-C30 v3.0 in Participants With Detectable PD-L1, Deterioration in GHS/HRQoL (Items 29, 30 of the EORTC QLQ C30) was defined by the following two criteria: 1. The time from randomization to the first time the participants's GHS/HRQoL scale score showed a \>=10-point decrease from the baseline scale score. A 10-point change was defined as the minimally important difference (MID). 2. The score decrease of \>= 10-points from baseline was held for at least two consecutive cycles, or an initial score decrease of \>= 10-points was followed by death or treatment discontinuation within 3 weeks from the last assessment., Baseline up to approximately 58 months|Percentage of Participants With at Least One Adverse Event, Percentage of participants with at least one adverse event., Baseline up to to the data cutoff date: 31 August 2021 (up to approximately 74 months)|Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab, Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab, Baseline up to approximately 53 months|Maximum Serum Concentration (Cmax) for Atezolizumab, Maximum serum concentration for atezolizumab., Cycle 1 Day 1 (Cycle = 28 days)|Minimum Serum Concentration (Cmin) for Atezolizumab, Minimum serum concentration for atezolizumab., Day 27 of Cycle 1, 2, 3, and 7 (Cycle = 28 days)|Plasma Concentrations of Total Paclitaxel, Plasma Concentrations of Total Paclitaxel, Pre-dose (Hour 0) on Cycle 1 Day 1, pre-dose (Hour 0), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after end of nab-paclitaxel infusion (infusion duration = 30 minutes) on Cycle 3 Day 1 (Cycle = 28 days)",,Hoffmann-La Roche,,ALL,"ADULT, OLDER_ADULT",PHASE3,902,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",WO29522|2014-005490-37,2015-06-23,2020-04-14,2021-08-31,2015-04-24,2021-05-17,2022-07-19,"University of Alabama at Birmingham, Birmingham, Alabama, 35249, United States|Highlands Oncology Group, Springdale, Arkansas, 72762, United States|Kaiser Permanente of Northern California, Oakland, California, 94612, United States|Emad Ibrahim, Md, Inc, Redlands, California, 92373, United States|Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, 94115, United States|Kaiser Permanente - San Marcos, San Marcos, California, 92069, United States|Cancer Research Collaboration, Inc., Santa Ana, California, 92705, United States|Stanford Univ School of Med; Oncology, Stanford, California, 94305-5821, United States|Kaiser Permanente Of Colorado, Aurora, Colorado, 80014, United States|Yale Cancer Center; Medical Oncology, New Haven, Connecticut, 06520, United States|Norwalk Hospital, Norwalk, Connecticut, 06856, United States|Stamford Hospital; BCC, MOHR, Stamford, Connecticut, 06904, United States|MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington, District of Columbia, 20007, United States|Florida Cancer Specialists - SCRI; Pharmacy, Fort Myers, Florida, 33901, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, 32256, United States|The Mount Siani Comprehensive Cancer Center, Miami Beach, Florida, 33140, United States|Florida Cancer Research Institute, Plantation, Florida, 33324, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, 33705, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, 30060, United States|Rush University Medical Center - Chicago, Chicago, Illinois, 60612, United States|Mercy Medical Center, Baltimore, Maryland, 21202, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States|Maryland Oncology Hematology, Rochville, Maryland, 20850, United States|Barbara Ann Karmanos Cancer Institute; Oncology, Detroit, Michigan, 48201, United States|West Michigan Cancer Center, Kalamazoo, Michigan, 49007, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, 39202, United States|Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC, Kansas City, Missouri, 64132, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|New Hampshire Hematology Oncology, Manchester, New Hampshire, 03103, United States|The Valley Hospital, Ridgewood, New Jersey, 07450, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|ProHEALTH Care Associates LLP, Lake Success, New York, 11042, United States|Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, 10016, United States|Onc/Hem Care Clin Trials LLC, Cincinnati, Ohio, 45242, United States|The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, 43219, United States|Kaiser Perm NW - Rheuma, Portland, Oregon, 97227, United States|Providence Cancer Center, Portland, Oregon, 97231, United States|St. Luke's Cancer Care Associates, Bethlehem, Pennsylvania, 18015, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, 15213, United States|Greenville Health System (GHS) Cancer Institute, Greenville, South Carolina, 29605, United States|Wellmont Bristol Regional Medical Center, Bristol, Tennessee, 37620, United States|West Clinic, Germantown, Tennessee, 38138, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, 37203, United States|Vanderbilt, Nashville, Tennessee, 37232, United States|Texas Oncology- El Paso Cancer Treatment Center Gateway, El Paso, Texas, 79915, United States|The Methodist Cancer Center, Houston, Texas, 77030, United States|University of Texas;M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Inova Medical Group, Fairfax, Virginia, 22031, United States|Cancer Care Northwest, Spokane, Washington, 99204, United States|Centro de Oncologia e Investigacion Buenos Aires (COIBA), Buenos Aires, B1884BBF, Argentina|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, C1125ABD, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, F5300COE, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, 2050, Australia|Nepean Cancer Care Centre, Sydney, New South Wales, 2747, Australia|Icon Cancer Foundation, South Brisbane, Queensland, 4101, Australia|Princess Alexandra Hospital; Division of Cancer Services, Woolloongabba, Queensland, 4102, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, 3199, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, 3000, Australia|Sunshine Hospital, St Albans, Victoria, 3021, Australia|St John of God Hospital; Bendat Cancer Centre, Subiaco, Western Australia, 6008, Australia|Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, 8036, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, 4010, Austria|A.Ö. Lhk; Ii. Medizinische Abt. Mit Schwerpunkt Gaströnter. & Onkologie, Steyr, 4400, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, 1090, Austria|Institut Jules Bordet, Anderlecht, 1070, Belgium|Cliniques Universitaires St-Luc, Bruxelles, 1200, Belgium|GHdC Site Notre Dame, Charleroi, 6000, Belgium|AZ Groeninge, Kortrijk, 8500, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|Sint Augustinus Wilrijk, Wilrijk, 2610, Belgium|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, 7100, Bosnia and Herzegovina|Santa Casa de Misericordia de Salvador, Salvador, BA, 40050-410, Brazil|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CE, 60336-550, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, 74605-070, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, 98700-000, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, 90035-903, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, 90610-000, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, 88034-000, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, 88301-220, Brazil|Hospital Perola Byington, Sao Paulo, SP, 01317-000, Brazil|Hospital Sao Jose, Sao Paulo, SP, 01321-001, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, T2N 4N2, Canada|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre), Kelowna, British Columbia, V1Y 5L3, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, B3H 2Y9, Canada|Kingston General Hospital, Kingston, Ontario, K7L 2V7, Canada|Lakeridge Health Oshawa; Oncology, Oshawa, Ontario, L1G 2B9, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, K2H 6C2, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, M4N 3M5, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, G1S 4L8, Canada|Centro de Cancer Pontificie Universidad Catolica de Chile, Santiago, 8330074, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, 4810469, Chile|Clinica del Country, Bogota, 11001, Colombia|Oncomedica S.A., Monteria, 230002, Colombia|Clinica CIMCA, San José, 10103, Costa Rica|ICIMED Instituto de Investigación en Ciencias Médicas, San José, 10108, Costa Rica|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, 779 00, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, 128 08, Czechia|Fakultni nemocnice v Motole, Praha 5, 150 06, Czechia|North Estonia Medical Centre Foundation; Oncology Centre, Tallinn, 13419, Estonia|Tartu Uni Hospital; Hematology - Oncology Clinic, Tartu, 51014, Estonia|Tampere University Hospital; Dept of Oncology, Tampere, 33520, Finland|Ico - Paul Papin, Angers, 49000, France|Institut Sainte Catherine, Avignon, 84082, France|Hopital Jean Minjoz, Besancon, 25030, France|HOPITAL MICHALLON - CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE, Service d'oncologie Médicale, Grenoble, 38043, France|Centre Oscar Lambret, Lille, 59020, France|Centre Leon Berard, Lyon, 69008, France|Institut régional du Cancer Montpellier, Montpellier, 34298, France|Clinique Catherine de Sienne, Nantes, 44202, France|Institut Curie, Paris, 75005, France|Hopital La Pitie Salpetriere, Paris, 75013, France|Institut De Cancerologie De L'Ouest; Medical Oncology, Saint Herblain, 44115, France|Centre Paul Strauss, Strasbourg, 67000, France|Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, 13581, Germany|St. Johannes Hospital; Abt. für Hämatologie und Onkologie, Dortmund, 44137, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, 01307, Germany|Universitätsklinikum Erlangen; Frauenklinik, Erlangen, 91054, Germany|Uniklinik Essen; Gynäkologie, Essen, 45122, Germany|Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH, Georgsmarienhütte, 49124, Germany|Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie, Halle, 06120, Germany|Universitätsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, 20246, Germany|Facharztzentrum Eppendorf, Studien GbR, Hamburg, 20249, Germany|Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen, Heidelberg, 69120, Germany|Praxis Köppler, Heymann, Weide, Thomalla; Fä Für Innere Medizin, Koblenz, 56068, Germany|St. Elisabeth-Krankenhaus; Brustzentrum, Köln, 50935, Germany|Universitätsklinikum Schleswig-Holstein; Campus Lübeck, Lübeck, 23538, Germany|Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde, München, 81675, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Münster, 48153, Germany|MVZ Nordhausen gGmbH, Praxis Dr. Grafe, Nordhausen, 99734, Germany|Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie, Recklinghausen, 45659, Germany|Mutterhaus der Borromäerinnen gGmbH, Abteilung Hämatologie-Onkologie, Trier, 54290, Germany|Dres. Helmut Forstbauer, Carsten Ziske und Kollegen; Onkologische Schwerpunktpraxis, Troisdorf, 53840, Germany|Universitätsklinik Tübingen; Frauenklinik & Poliklinik, Tübingen, 72076, Germany|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, 115 22, Greece|IASO General Hospital of Athens, Athens, 155 62, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, 711 10, Greece|University Hospital of Patras Medical Oncology, Patras, 265 04, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, 546450, Greece|Grupo Angeles, Guatemala City, 01015, Guatemala|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, 1122, Hungary|Fövárosi Önkormányzat uzsoki utcai Kórház, Budapest, 1145, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, 6720, Hungary|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, 80131, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica, Milano, Lombardia, 20141, Italy|Aichi Cancer Center Hospital, Aichi, 464-8681, Japan|Fukushima Medical University Hospital, Fukushima, 960-1295, Japan|Gunma Prefectural Cancer Center, Gunma, 373-8550, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, 730-8518, Japan|Hiroshima University Hospital, Hiroshima, 734-8551, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, 003-0804, Japan|Hyogo Medical University Hospital, Hyogo, 663-8501, Japan|Sagara Hospital, Kagoshima, 892-0833, Japan|St. Marianna University Hospital, Kanagawa, 216-8511, Japan|Tokai University Hospital, Kanagawa, 259-1193, Japan|Kumamoto University Hospital, Kumamoto, 860-8556, Japan|Kyoto University Hospital, Kyoto, 606-8507, Japan|Mie University Hospital, Mie, 514-8507, Japan|Tohoku University Hospital, Miyagi, 980-8574, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Naha-nishi Clinic, Okinawa, 901-0154, Japan|National Hospital Organization Osaka National Hospital, Osaka, 540-0006, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|Saitama Medical University International Medical Center, Saitama, 350-1298, Japan|Saitama Cancer Center, Saitama, 362-0806, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|National Cancer Center Hospital, Tokyo, 104-0045, Japan|St. Luke's International Hospital, Tokyo, 104-8560, Japan|Komagome Hospital, Tokyo, 113-8677, Japan|The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan|National Cancer Center, Goyang-si, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|Daugavpils Regional Hospital, Daugavpils, 5417, Latvia|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, LV-1079, Latvia|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), 06760, Mexico|Centro Médico Zambrano Hellion, Monterrey, Nuevo LEON, 66278, Mexico|Instituto Estatal de Cancerologia Colima, Colima, 28000, Mexico|Iem-Fucam, D.f., 04980, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, 03100, Mexico|Helse Bergen HF Haukeland universitetssjukehus kreftavdelingen poliklinikk, Bergen, Norway|Sørlandet Sykehus Kristiansand, Kristiansand, 4604, Norway|Stavanger Universitetssykehus, Helse Stavanger HF, Stavanger, 4011, Norway|Centro Oncológico de Panamá, Panama, 0801, Panama|Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii, Bydgoszcz, 85-796, Poland|Szpitale Wojewodzkie w Gdyni Sp. z o.o., Gdynia, 81-519, Poland|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Kraków, 30-688, Poland|Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii, Lublin, 20-090, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr, Warszawa, 02-781, Poland|Wojskowy Instytut Medyczny, Warszawa, 04-141, Poland|Oncomed SRL, Timisoara, 300239, Romania|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Arhangelsk, 163045, Russian Federation|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, 143423, Russian Federation|Main Military Clinical Hospital named after N.N. Burdenko, Moscow, Moskovskaja Oblast, 105229, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moskva, Moskovskaja Oblast, 115478, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, 153040, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, 420029, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, 197758, Russian Federation|National University Hospital, Singapore, 119074, Singapore|National Cancer Centre, Singapore, 169610, Singapore|Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, 14004, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, 08003, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, 08035, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, 08907, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, 28041, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, 28046, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, 29010, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, 46009, Spain|Sodersjukhuset; Onkologkliniken, Stockholm, 118 83, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, 751 85, Sweden|Universitaetsspital Basel; Onkologie, Basel, 4031, Switzerland|Kantonsspital St.Gallen Brustzentrum/Chirurgie; Brustzentrum, St. Gallen, 9007, Switzerland|Universitätsspital Zürich, Zürich, 8038, Switzerland|Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery, Kaohsiung, 807, Taiwan|China Medical University Hospital; Surgery, Taichung, 404, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, 00112, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, 100, Taiwan|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, 10400, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, 10700, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, 90110, Thailand|Cukurova Uni Faculty of Medicine; Medical Oncology, Adana, 01330, Turkey|Istanbul University Cerrahpasa Medical Faculty; Radiation Oncology Department, Istanbul, 34098, Turkey|Medipol University MF; Oncology Department, Istanbul, 34214, Turkey|Ege Uni Medical Faculty Hospital; Oncology Dept, Izmir, 35100, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, 06230, Turkey|Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, 49102, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, 03115, Ukraine|Treatment and Prevention Institution Volyn Regional Oncology Dispensary, Lutsk, 43018, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv, 79031, Ukraine|Velindre Cancer Centre, Cardiff, CF14 2TL, United Kingdom|Western General Hospital; Clinical Oncology, Edinburgh, EH4 2XU, United Kingdom|St Bartholomew's Hospital, London, EC1M 6BQ, United Kingdom|Guys ST Thomas Hospital, London, SE1 9RT, United Kingdom|Royal Marsden Hospital - London, London, SW3 6JJ, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, M2O 4BX, United Kingdom|Derriford Hospital, Plymouth, PL6 8DH, United Kingdom|Royal Preston Hosptial, Preston, PR2 9HT, United Kingdom|Weston Park Hospital, Sheffield, S10 2SJ, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, SM2 5PT, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/91/NCT02425891/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/91/NCT02425891/SAP_001.pdf"
